Immix Biopharma IMMX Stock
Immix Biopharma Price Chart
Immix Biopharma IMMX Financial and Trading Overview
| Immix Biopharma stock price | 2.76 USD |
| Previous Close | 2.03 USD |
| Open | 2.05 USD |
| Bid | 0 USD x 2900 |
| Ask | 0 USD x 800 |
| Day's Range | 2.03 - 2.37 USD |
| 52 Week Range | 0.68 - 3.35 USD |
| Volume | 270.09K USD |
| Avg. Volume | 346.04K USD |
| Market Cap | 35.48M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.89 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11 USD |
IMMX Valuation Measures
| Enterprise Value | 19.02M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.2777774 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.7962084 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.022 |
Trading Information
Immix Biopharma Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -2.88% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.35 USD |
| 52 Week Low | 0.68 USD |
| 50-Day Moving Average | 2.02 USD |
| 200-Day Moving Average | 1.82 USD |
IMMX Share Statistics
| Avg. Volume (3 month) | 346.04K USD |
| Avg. Daily Volume (10-Days) | 162.24K USD |
| Shares Outstanding | 15.03M |
| Float | 6.58M |
| Short Ratio | 0.37 |
| % Held by Insiders | 62.34% |
| % Held by Institutions | 3.72% |
| Shares Short | 220.31K |
| Short % of Float | 2.70% |
| Short % of Shares Outstanding | 1.46% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -35.39% |
| Return on Equity (ttm) | -59.86% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -9407644 USD |
| Net Income Avi to Common (ttm) | -9377329 USD |
| Diluted EPS (ttm) | -0.68 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.46M USD |
| Total Cash Per Share (mrq) | 0.76 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 8.849 |
| Book Value Per Share (mrq) | 0.844 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8005477 USD |
| Levered Free Cash Flow (ttm) | -4450804 USD |
Profile of Immix Biopharma
| Country | United States |
| State | CA |
| City | Los Angeles |
| Address | 11400 West Olympic Boulevard |
| ZIP | 90064 |
| Phone | 310 651 8041 |
| Website | https://www.immixbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 9 |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Q&A For Immix Biopharma Stock
What is a current IMMX stock price?
Immix Biopharma IMMX stock price today per share is 2.76 USD.
How to purchase Immix Biopharma stock?
You can buy IMMX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immix Biopharma?
The stock symbol or ticker of Immix Biopharma is IMMX.
Which industry does the Immix Biopharma company belong to?
The Immix Biopharma industry is Biotechnology.
How many shares does Immix Biopharma have in circulation?
The max supply of Immix Biopharma shares is 26.4M.
What is Immix Biopharma Price to Earnings Ratio (PE Ratio)?
Immix Biopharma PE Ratio is now.
What was Immix Biopharma earnings per share over the trailing 12 months (TTM)?
Immix Biopharma EPS is -0.89 USD over the trailing 12 months.
Which sector does the Immix Biopharma company belong to?
The Immix Biopharma sector is Healthcare.
Immix Biopharma IMMX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}